Mercado global de tratamento do leiomiossarcoma – Tendências do setor e previsão para 2030

Análise e dimensão do mercado de tratamento do leiomiossarcoma

O mercado global de tratamento do leiomiossarcoma tem registado um crescimento significativo devido ao aumento da prevalência de sarcomas de tecidos moles é um dos fatores impulsionadores para o mercado global de tratamento do leiomiossarcoma. Por exemplo, nos EUA, o total de novos casos diagnosticados de sarcomas de tecidos moles é de 13.460 e 5.350 pessoas que deverão morrer devido a este tipo de cancro. O aumento da população feminina com miomas pode ter hipóteses de desenvolver LMS, ou seja, uma em cada cinco em cada 1.000 mulheres sofre deste cancro, que atua como um motor para o crescimento global do mercado de tratamento do leiomiossarcoma. Os efeitos secundários relacionados com a quimioterapia e radioterapia do LMS podem dificultar o crescimento global do mercado de tratamento do leiomiossarcoma. Por exemplo, problemas de pele, fadiga, desconforto estomacal, problemas sexuais especialmente na população masculina, boca seca, anemia, queda de cabelo e muitos outros efeitos secundários.                     

A Data Bridge Market Research analisa que o mercado global de tratamento do leiomiossarcoma, que foi de 584,12 milhões de dólares em 2022, deverá atingir os 834,12 milhões de dólares até 2030, e deverá passar por um CAGR de 4,30% durante o período de previsão de 2023 a 2030. “Baixo grau” domina o segmento de grau do mercado global de tratamento do leiomiossarcoma devido ao aumento das taxas de incidência. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços, e quadro regulamentar.

Âmbito e segmentação do mercado de tratamento do leiomiossarcoma

Definição de mercado

O leiomiossarcoma (LMS) é um tipo de sarcoma de tecidos moles que afeta principalmente o tecido muscular liso. Este tipo de tumor pode afetar qualquer parte do corpo, como o estômago, o intestino, a bexiga, os vasos sanguíneos, o fígado e muitos outros, mas afeta essencialmente o abdómen, incluindo o útero. O tratamento do leiomiossarcoma abrange todos os produtos farmacêuticos, terapias e intervenções médicas destinadas a diagnosticar, tratar ou controlar o leiomiossarcoma. Estes produtos incluem quimioterapia, radioterapia, terapias dirigidas, imunoterapias, intervenções cirúrgicas e opções de cuidados paliativos.

Dinâmica global do mercado de tratamento do leiomiossarcoma

Motoristas

• Avanços na investigação do cancro

Os avanços contínuos no campo da investigação do cancro melhoraram significativamente a nossa compreensão dos mecanismos subjacentes e das vias moleculares envolvidas no leiomiossarcoma. Este conhecimento aprofundado abriu caminho para o desenvolvimento de opções de tratamento mais direcionadas e eficazes. Os investigadores conseguem agora conceber terapias que visem especificamente as características únicas das células do leiomiossarcoma, minimizando os danos nos tecidos saudáveis ​​e levando potencialmente a melhores resultados para os doentes.

• Aumento das taxas de incidência

Although leiomyosarcoma is considered a rare cancer, its incidence has been gradually increasing over the years. This rise can be attributed to several factors, including improved diagnostic techniques, increased awareness among healthcare providers, and potentially changing environmental factors. The growing number of leiomyosarcoma cases drives the demand for effective treatments and contributes to the expansion of the global leiomyosarcoma treatment market.

• Emerging of Treatment Modalities

Traditional treatments for leiomyosarcoma, such as surgery, chemotherapy, and radiation therapy, have limitations and can be associated with significant side effects. However, emerging treatment modalities, including precision medicine and immunotherapy, offer promising alternatives. Precision medicine involves tailoring treatment plans to the specific genetic characteristics of a patient's tumor, potentially improving treatment outcomes and reducing adverse effects. Immunotherapy harnesses the body's immune system to target and destroy cancer cells, offering a more targeted and less toxic approach to treatment.

Opportunities

• Increase Demand of Immunotherapy

Collaboration among pharmaceutical companies, academic institutions, and healthcare organizations can accelerate research and development in the leiomyosarcoma treatment field. By pooling resources, expertise, and data, collaborative efforts can overcome the challenges associated with rare diseases, ultimately leading to the development of more effective treatments.

• Collaborative Research Efforts

The rise of telemedicine and remote monitoring technologies has transformed the way healthcare is delivered. These technologies enable healthcare providers to remotely monitor emphysema patients, assess their condition, and adjust treatment plans as needed. Telemedicine improves access to care, especially for patients in rural or underserved areas. It also enhances patient education and medication adherence, ultimately leading to better disease management and outcomes

Restraints/Challenges

• Limited Treatment Options

The, leiomyosarcoma has had few available treatment options, primarily relying on surgery, chemotherapy, and radiation therapy. The limited arsenal of treatments poses challenges, particularly for patients who do not respond well to these standard approaches. The development of additional effective treatments is crucial to addressing the diverse needs of leiomyosarcoma patients.

• Rare Disease Status

Leiomyosarcoma is classified as a rare disease, which poses unique challenges for research and development efforts. Limited patient populations make it difficult to conduct large-scale clinical trials and gather sufficient data to support the approval of new treatments. This rarity also affects the overall size and growth potential of the leiomyosarcoma treatment market, making it less attractive to pharmaceutical companies.

This global leiomyosarcoma treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global leiomyosarcoma treatment market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In January 2020, Epizyme, Inc., received the U.S. Food and Drug Administration (FDA) approval for Tazverik, a target specific drug indicated for the treatment of epithelioid sarcoma in patients of age 16 and above

Global Leiomyosarcoma Treatment Market Scope

The global leiomyosarcoma treatment market is segmented on the basis of grade, classification, diagnosis, treatment, and end-user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Grade

• Low Grade
• High Grade
• Others

Classification

• Leiomyosarcoma of Soft Tissue
• Leiomyosarcoma of Cutaneous Origin
• Leiomyosarcoma of Vascular Origin
• Leiomyosarcoma in the Immunocompromised Host
• Leiomyosarcoma of Bone

Diagnosis

• Blood Test
• Ultrasound
• Computed Tomography (CT) Scan
• Magnetic Resonance Imaging (MRI) Scan

Treatment

• Surgery
• Radiotherapy
• Chemotherapy
• Doxorubicin and Ifosfamide
• Gemcitabine and Taxotere (Docetaxel)
• Dacarbazine and Ecteinascidin

End-User

• Cancer Research Institutes
• Diagnostic Laboratories
• Hospitals
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

Global Leiomyosarcoma Treatment Market Regional Analysis/Insights

The global leiomyosarcoma treatment market is analysed and market size insights and trends are provided by country, grade, classification, diagnosis, treatment, end-user and distribution channel as referenced above.

The countries covered in the global leiomyosarcoma treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the global leiomyosarcoma treatment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is because of the increase in the expenditure for research and development proficiencies, increasing government’s initiatives and improved health care infrastructure in various countries.

Asia-Pacific on the other hand is projected to exhibit the highest growth rate in the global leiomyosarcoma treatment market during the forecast period of 2023 to 2030 owing to the increasing government expenditure on healthcare sector and rising technological advancements and initiatives by the government.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Leiomyosarcoma Treatment Market Share Analysis

The global leiomyosarcoma treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global leiomyosarcoma treatment market.

Some of the major players operating in the global leiomyosarcoma treatment market are:

• GSK plc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland)
• Astrazeneca (U.S.)
• Pfizer Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Sanofi (U.S.)
• Amgen Inc. (U.S.)
• Daiichi Sankyo Company Limited (Japan)
• AB Sciences (France)
• Eisai Co., Ltd (Japan)
• Genentech Inc. (U.S)
• Merck & Co., Inc. (U.S.)

SKU-60050